| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.26 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.03 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.087 | 0.03 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |